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a b s t r a c t
Adenosine deaminase acting on RNA1 (ADAR1) was previously reported to affect HIV-1 replication. We
report data showing that ADAR1 interacts with the HIV-1 p55 Gag protein, the major structural protein
of the immature virus capsid. Furthermore, we found that the endogenous ADAR1 is incorporated into
virions puriﬁed from the supernatant of primary HIV-1-infected CD4þ T lymphocytes. Additional
experiments demonstrated that the expression of the p55 Gag protein is sufﬁcient for ADAR1
incorporation into virus-like particles (VLPs).
Overall, our data originally support the evidence that ADAR1 can be part of the cell protein array
uploaded in HIV-1 particles.
& 2015 Elsevier Inc. All rights reserved.
Introduction
Adenosine deaminases that act on RNA (ADARs) catalyze the
conversion of adenosine (A) to inosine (I) within a double-
stranded RNA (RNA editing A to I) (George et al., 2014). Three
ADAR enzymes were described in mammalian cells (ADAR1-3), but
only ADAR1 and ADAR2 appear catalytically active (Valente and
Nishikura, 2005).
There are two ADAR1 isoforms generated by the use of
alternative promoters and splicing: the full length p150 ADAR1
form that is interferon-inducible, and the short p110 ADAR1 form
that is constitutively expressed (Patterson and Samuel, 1995).
ADAR1 proteins have a catalytic domain at the C-terminal, three
double-stranded RNA binding motifs in the central region (dsRBD),
and Z-DNA binding motifs at the N-terminal (Zβ in p110; Zα and
Zβ in p150) (George et al., 2014). Since I is recognized as guanosine
(G) by the cellular machinery, RNA editing by ADARs can lead to
the formation of an altered protein when occurring within the
coding sequence of a mRNA (Valente and Nishikura, 2005; Savva et
al., 2012). Nonetheless, it has been recently demonstrated that
most A-to-I RNA editing events occur within non-coding regions,
introns, and untranslated regions (UTRs), affecting different
aspects of RNA metabolism (Valente and Nishikura, 2005; Savva
et al., 2012).
Increasing lines of evidence indicate that ADAR1 plays an
important role in the replication process of different viruses,
although there is no general consensus on the mechanism
involved (i.e. dependent or not on the RNA editing activity) and
on the outcome (either proviral or antiviral), possibly due to
differences in the nature of the virus and the host cell being
investigated (Samuel, 2011). Concerning HIV-1, most of the pub-
lished data strongly indicates that ADAR1 exerts a positive effect
on viral replication (Phuphuakrat et al., 2008; Clerzius et al., 2009;
Doria et al., 2009; Clerzius et al., 2013), although some contrasting
results have been reported (Biswas et al., 2012; Weiden et al.,
2014). We and others showed that over-expressed ADAR1
increases the accumulation of HIV-1 proteins with a mechanism
that is editing-independent probably by inhibiting the interferon
(IFN)-inducible Protein Kinase RNA-activated (PKR) (Clerzius et al.,
2009; 2013; Doria et al., 2009) that is a key modulator of
translation initiation of viral and cellular mRNAs (Burugu et al.,
2014). Moreover, we demonstrated that virions produced in the
presence of over-expressed wt ADAR1, but not of an editing-
inactive ADAR1 mutant, are released more efﬁciently and display
enhanced infectivity (Doria et al., 2009). Furthermore, binding and
editing of viral transcripts mediated by ADAR1 was clearly demon-
strated (Phuphuakrat et al., 2008; Doria et al., 2009). In particular,
A-to-I editing was identiﬁed in the 50 untranslated region (50UTR)
and within the Tat and Rev sequences and in the vicinity of Rev
responsive element (RRE) RNA within the Env gene (Phuphuakrat
et al., 2008; Doria et al., 2009). Finally, silencing of ADAR1
expression in Jurkat T cells causes impairment of HIV-1 replication
(Clerzius et al., 2013).
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Here, we address the question whether ADAR1 associates with
viral proteins during HIV-1 replication.
We show that ADAR1 interacts with the HIV-1 p55 Gag protein,
the major structural protein of the immature virus capsid and that
the endogenous ADAR1 is incorporated into virions puriﬁed from
the supernatant of primary HIV-1-infected CD4þ T lymphocytes.
Furthermore, we report that the sole expression of the p55 Gag
protein is sufﬁcient for ADAR1 incorporation into virus-like
particles (VLPs). Taken together, our results shed a new light on
the role of ADAR1 in HIV-1 replication.
Material and methods
Cells and transfection
293 GPR and 293T cells were grown in Dulbecco's modiﬁed
Eagle's medium, 10% fetal calf serum and transfected by using
Lipofectamine 2000 (Invitrogen).
CD4þ T lymphocytes were isolated from the peripheral blood
mononuclear cells of healthy donors by immunomagnetic-based
negative selection.
Virion puriﬁcation
CD4þ T lymphocytes were infected with VSV-G pseudotyped
HIV-1 (NL4-3 strain), which was prepared as previously described
(Federico et al., 2001) and used at 200 ng CAp24 equivalent/106
cells. After 24 h, the cell cultures were extensively washed, and
after additional 24 h, the percentage of HIV-1-expressing cells was
scored by FACS analysis using the anti-CAp24 KC57 mAb as
described (Federico et al., 2001). In the presence of 450% infected
cells, the supernatants were harvested, ﬁltered through 0.45 μM
pore size, loaded on 20% sucrose cushion, and ultracentrifuged at
100,000g for 2.5 h at 4 1C. Iodixanol gradient puriﬁcation was
performed as previously described (Dettenhofer and Yu, 1999).
Brieﬂy, concentrated vesicles were ultracentrifuged at 200,000 g
for 1.5 h at 4 1C in an SW41 Ti rotor (Beckman) through a 6–18%
iodixanol density gradient formed by layering iodixanol in 1.2%
increments. Then, 0.7 ml fractions were collected starting from the
top and titrated by measuring HIV-1 CAp24 contents by quantita-
tive ELISA (Innogenetics).
VLP production
293 GPR cells were used as HIV-1 packaging cells for VLPs
production, as previously reported (Sparacio et al., 2001). In 293
GPR cells, the gag-pol genes are under the control of an ecdysone-
inducible promoter, so that the lentiviral particle production
requires cell stimulation with the ecdysone analog ponasterone
A (PonA). It was previously shown (Sparacio et al., 2001) that
adding to the cell medium butyrate (general inducer of gene
expression) together with PonA results in a stimulation of HIV
Gag/Pol particle expression to remarkably high levels compared to
the stimulation with the PonA alone. Therefore, transfected 293
GPR cells were induced with 5 mM sodium butyrate and 2 μM
PonA 8 h post-transfection. After 24 h, supernatants were replaced
with fresh medium containing both inducers. VLP containing
supernatants were ﬁnally harvested from 24 to 48 h later and
clariﬁed, and concentrated by ultracentrifugation on 20% sucrose
cushion at 100,000 g, for 2 h at 4 1C. VLP preparations were
titrated by measuring HIV-1 CAp24 contents by quantitative ELISA
(Innogenetics) and by reverse transcriptase assay processed as
previously reported (Di Bonito et al., 2009).
Plasmids
The following vectors were previously described: pADAR1-
p150-V5 (expressing the full length p150 ADAR1 enzyme fused
with a C-terminal V5/6xHis double tag; Clerzius et al., 2009), pV5
vector (pcDNA3.1/V5 empty vector), pBabe-BCL2 (Sgadari et al.,
2011), pEGFP-Gag (a vector expressing p55 Gag fused with the
EGFP protein to its N-terminus NIH, AIDS Reagent Program catalog
number 11468), hGag-Flag (a vector expressing the p55 Gag fused
with the Flag sequence to its C-terminus) or derivative Gag
mutants D378-Flag, that lacks the NC-p6 domains, and D133-Flag,
that lacks the CA-NC-p6 domains, as previously described (Ma et
al., 2008), pNL4-3 (HIV-1 proviral DNA).
Dual tag afﬁnity puriﬁcation
10106 293T cells were co-trasfected with 8 μg of the proviral
DNA (pNL4-3) together with 12 μg of either pADAR1-p150-V5
(expressing the full length p150 ADAR1 enzyme fused with a C-
terminal V5/6xHis double tag; Clerzius et al., 2009) or pV5 vector
(pcDNA3.1/V5 empty vector).
Transfected 293T cells were lysed in NP40 buffer (0.5% NP40,
50 mM Tris–HCl, 150 mM NaCl, 0.05% Tween 20, 50 mM NaH2PO4,
pH 8, cocktails of protease and phosphates inhibitors from Roche
and SIGMA, respectively) supplemented with 10 mM imidazole for
30 min on ice. Two milligrams of cell extracts were incubated with
40 μl of the NiNTA Magnetic Beads (Qiagen) for 3 h at 4 1C
followed by several washes (using NP40 buffer with 20 mM
imidazole) and elution of His-tagged native protein complex from
the beads (using NP40 buffer with 250 mM imidazole). The eluted
protein complex was then subjected to a second step of immuno-
precipitation (Ip) using the anti-V5-tag magnetic beads (MBL) for
2 h at 4 1C followed by several washes with NP40 buffer. When
indicated, RNase V1 (0.002 U/μl, Life Technologies) and RNase A
(0.1 μg/μl, Sigma-Aldrich) were added to the cell extract and
incubated at room temperature for 30 min before the Ip. The
complete degradation of total RNA was assayed by loading a
fraction (10 μg) of the treated and untreated cell extract on 1%
agarose gel followed by electrophoresis and ethidium bromide
staining. The Ip fraction and 20 μg of the total cell extract (input)
were resolved by SDS-PAGE and transferred onto Nitrocellulose
Membrane, and immunoblotted using speciﬁc antibodies.
Protein immunoprecipitation
293T cells transfected with 5 μg pADAR1-p150-V5 together
with 5 μg of either pEGFP-Gag or pGFP or hGag-Flag or the
truncated versions of hGag-Flag (D378-Flag and D133-Flag)
expression vectors were lysed in NP40 buffer for 30 min on ice.
Two milligrams of cell extracts were pre-cleared on IgG/dynabeads
protein G (Invitrogen) and then co-Ip for 3 h at 4 1C with rotation
using mAb either anti-V5 (Invitrogen) or anti-GFP (Invitrogen) or
anti-Flag (Sigma-Aldrich) or control IgG (Santa Cruz Biotechnol-
ogy) followed by incubation with dynabeads protein G (Invitro-
gen) for 3 h at 4 1C with rotation. The Ip fraction and 20 μg of the
total cell extract (input) were resolved by SDS-PAGE and trans-
ferred onto Nitrocellulose Membrane and blot analyzed using
speciﬁc antibodies.
Antibodies
The antibodies used were: anti-V5 (Invitrogen), anti-GFP (Invi-
trogen), AG3.0 anti-capsid antigen (CA) p24 antibody (NIH AIDS
Research and Reference Program), anti-BCL2 (Santa Cruz Biotech-
nology), anti-Flag (Sigma-Aldrich), anti-APOBEC3G (ImmunoDiag-
nostics) and anti-ADAR1 (Santa Cruz Biotechnology).
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Results and discussion
ADAR1 associates with HIV-1 p55 Gag
To better understand how ADAR1 facilitates HIV-1 replication,
we sought to investigate whether the enzyme associates with viral
proteins. To this aim, we employed a dual tag afﬁnity puriﬁcation
procedure that allows identiﬁcation of target-associated native
protein complexes with low background to process total cell
extracts of 293T cells co-transfected with proviral DNA (pNL4-3),
together with either pADAR1-p150-V5 or pV5 empty vector. The
ﬁnal immunoprecipitated complex was then analyzed together
with an aliquot of total cell lysate by Western Blotting (WB) using
anti-V5 mAb (Invitrogen) and total serum of an HIV-1-infected
patient (Fig. 1a). The anti-V5 mAb revealed the full-length ADAR1
protein of 150 kDa and a shorter form of about 110 kDa that is
consistent with a protein translation initiation at a second
methionine at position 296 reported in a previous study
(Desterro et al., 2003) (Fig. 1a, left panel).
The anti-HIV-1 serum allowed the detection of a viral protein
with an apparent molecular mass of about 55 kDa that co-
immunoprecipated (co-Ip) only with the ADAR1-V5 proteins
(Fig. 1a, right panel).
The 55 kDa molecular mass suggested a possible interaction
between ADAR1 and the viral p55 Gag protein. Indeed, this
hypothesis was conﬁrmed using anti-p24 antibody (Fig. 1b). Treat-
ment with RNase mix (RNase AþRNAse V1) of the total cell extract
prior Ip experiments, substantially reduce the association between
ADAR1 and p55 Gag, suggesting that this interaction is mostly
dependent on RNA bridging molecules (Fig. 1b). The complete
Fig. 1. The viral p55 Gag protein interacts with ADAR1. (a) Lysates of 293T cells co-transfected with either pV5 or pADAR1-p150-V5 plasmids and the HIV-1 proviral genome
(NL4-3) were subjected to a dual Tag afﬁnity puriﬁcation (IP) under native condition followed by WB analysis with anti-V5 mAb and total serum of an HIV-1-infected patient
(right panel). In the left panel, WB analysis of 20 μg of cell lysate inputs (Lysate) is shown. The asterisk indicates ADAR1 protein of about 110 kDa produced by translation
machinery from a second methionine at position 296. The double asterisk indicates an unspeciﬁc protein detected in both the immunoprecipitates. The arrow indicates an
immunoprecipated viral protein with an apparent molecular weight of about 55 kdA. (b) Lysates of 293T cells co-transfected with either pV5 or pADAR1-p150-V5 plasmids
and the proviral NL4-3 genome was subjected to a dual Tag afﬁnity puriﬁcation (IP) under native condition followed by WB analysis with anti-V5 and anti-p24 mAbs (right
panel). The cell lysates were mock-treated or RNase (AþV1)-treated prior to immunoprecipitation. The double asterisk indicates the IgG light chains. In the left panel, WB
analysis of 20 μg of the cell lysate inputs (Lysate) is shown. (c) Lysates of 293T cells co-transfected with pEGFP-Gag and pADAR1-V5 were immunopreciptated (IP) with either
anti-V5 or anti-GFP antibodies or control IgGs followed by WB analysis with anti-V5 and anti-GFP mAbs. In the left panel, the WB analysis of 20 μg of the cell lysate inputs
(Lysate) is shown. (d) Schematic representation of the Gag-Flag and Gag mutants employed. Lysates of 293T cells transfected with pADAR1-p150-V5 plasmid together with
either hGag-Flag (expressing the wt Gag) or the truncated versions D378-Flag (expressing a Gag mutant that lacks the NC-p6 domains) or D133-Flag (expressing a Gag
mutant that lacks the CA-NC-p6 domains) plasmids were immunoprecipitated with an anti-Flag antibody (IP FLAG) or IgGs (IP IgG) followed byWB analysis with anti-V5 and
anti-Flag mAbs. The double asterisk indicates the IgG heavy chains, the single asterisk indicates the IgG light chains. In the left panel, WB analysis of 20 μg of the cell lysate
inputs (Lysate) is shown.
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digestion of RNA prior Ip was conﬁrmed by analyzing the total
RNA in the RNase-treated lysate on 1,2% agarose gel (Fig. S1a) and
by reprobing the same ﬁlter shown in Fig. 1b with antibodies
against speciﬁc factors that associate with ADAR1 in RNA-
dependent manner (our unpublished data).
The association between ADAR1 and the HIV-1 p55 Gag protein
was further conﬁrmed by co-Ip experiments in the absence of
whole HIV-1 expression. Speciﬁcally, cell lysates prepared from
293T cells co-transfected with either pADAR1-p150-V5 or the pV5
vector together with pEGFP-Gag or pEGFP vectors, were immmu-
noprecipitated with either an anti-V5 or anti-GFP antibody or
control IgG (Santa Cruz Biotechnology). The WB analysis of the
resulting immunocomplexes with speciﬁc antibodies showed that
EGFP-Gag co-immunoprecipitated with ADAR1-V5 and that, inver-
sely, ADAR1-V5 co-immunoprecipitated with EGFP-Gag (Fig. 1c).
The interaction between ADAR1-V5 and GFP-Gag is speciﬁc, since
GFP protein expressed alone did not interact with ADAR1-V5 (Fig.
S1b). Moreover, to identify the Gag sequence necessary for the
interaction with
ADAR1, we used in co-Ip experiments a Gag-Flag construct
(expressing p55 Gag fused at its C-terminus to a Flag sequence)
and a panel of two derivative Gag mutants, D378-Flag and D133-
Flag, that lack the NC-p6 and CA-NC-p6 domains, respectively
(Fig. 1d, upper panel). ADAR1 efﬁciently associated with each Flag-
tagged protein
(Fig. 1d, bottom panel), thus showing that MA region of Gag is
sufﬁcient for Gag-ADAR1 interaction. Overall, we provided evidence
that brings to light a novel interaction between HIV-1 p55 Gag protein
and the RNA editing enzyme ADAR1 that might be pivotal for viral
replication.
ADAR1 p150 shuttles between nucleus and cytoplasm but is
predominantly cytoplasmic whereas ADAR1 p110 is mainly localized
in the nucleus of the cells (Patterson and Samuel, 1995; Poulsen et al.,
2001). Therefore, ADAR1 p150 may possibly interact with p55 Gag
within the cytoplasm of the cells where the virus assembly occurs.
ADAR1 is incorporated into HIV-1 virions
The p55 Gag precursor protein plays a central role in the assembly
of HIV-1 virions and in the selection of genomic RNA. It consists of the
matrix (MA), CA, nucleocapsid (NC), and p6 or ‘late’ domains, with the
CA/NC and the NC/p6 domains being separated by p2 and p1 linker
peptides, respectively (Lingappa et al., 2014).
Since ADAR1 interacts with p55 Gag (this study) and binds as
well the viral 9 kb RNA (Doria et al., 2009), we sought to
investigate whether ADAR1 could be incorporated in HIV-1 parti-
cles. To this aim, we puriﬁed virions released by CD4þ T lympho-
cytes infected with HIV-1 through a iodixanol density gradient and
analyzed 1 μg CAp24 equivalent of virus by WB analysis using the
anti-ADAR1, anti-p24 or anti-APOBEC3G mAbs (Fig. 2). Results
clearly demonstrated the presence in viral particles of endogenous
ADAR1 as well as APOBEC3G, a virion incorporated cellular
enzyme (Cen et al., 2004; Schäfer et al., 2004) that was used as
a positive control (Fig. 2, right panel).
ADAR1 is incorporated into VLPs
The p55 Gag protein is necessary and sufﬁcient for particle
assembly and its expression alone allows the production of virus-
like particles (VLPs) (Gheysen et al., 1989). We then tested whether
Fig. 2. ADAR1 is encapsidated in viral particles. HIV-1 particles were puriﬁed by
iodixanol density gradient from the supernatant of HIV-1-infected primary CD4þ T
lymphocytes and analyzed by WB (right panel) together with total cell extract of
the infected cells (left panel) using anti-ADAR1, anti-APOBEC3G and anti-p24 mAbs.
Fig. 3. ADAR1 is encapsidated in VLPs. (a) 293 GPR cells stably expressing the gag-pol genes under the control of an ecdysone-inducible promoter were transiently
transfected with the either pV5 or pADAR1-p150-V5 plasmids or the BCL2 expressing vector. Eight hours post-transfection Gag-Pol expression was induced with 5 mM
sodium butyrate and 2 μM of PonA. Twenty-four hours post-induction the VLPs were puriﬁed from the cell supernatants and analyzed (right panel) together with the total
cell extract (left panel) by WB with anti-V5, anti ADAR1 and anti-BCL2 mAbs. (b) Western Blotting analysis with anti-V5 and anti-p24 mAbs of increasing amounts (from 2 to
20 μl) of VLPs puriﬁed from 293 GPR cells transfected with pADAR1-V5 and either induced (þ) or not () with PonA (right panel) together with total cell extract of the
transfected 293 GPR cells but non induced with PonA (left panel).
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the expression of p55 Gag was sufﬁcient for the packaging of the
ADAR1 enzyme into VLPs.
To this aim, 293 GPR cells were used as HIV-1 packaging cells for
VLPs production, as previously reported (Sparacio et al., 2001). In 293
GPR cells, the gag-pol genes are under the control of an ecdysone-
inducible promoter, so that the lentiviral particle production requires
cell stimulation with the ecdysone analog ponasterone A (PonA) and
sodium butyrate (a general inducer of gene expression). Therefore, 293
GPR cells were transiently transfected with either pADAR1-p150-V5 or
pV5 or BCL2 expressing vectors (used as negative control for encapsi-
dation, Sgadari et al., 2011). Eight hours post-transfection, cells were
induced with sodium butyrate and PonA and afterwards VLPs were
puriﬁed from the supernatants of transfected cells as previously
reported (Di Bonito et al., 2009). Next, 10 μl of puriﬁed VLPs were
analyzed by WB using speciﬁc antibodies (Fig. 3a). Remarkably, while
in cell lysate the ectopically expressed ADAR1-V5 as well as the BCL2
protein were readily detected (Fig. 3a, left panel), ADAR1 but not BCL2
was found in puriﬁed VLPs (Fig. 3a, right panel). At last, increasing
amounts of VLPs (2, 5, 10, 20 μl) puriﬁed from unstimulated (Pon A )
or stimulated (Pon A þ) cells expressing ADAR1-V5 were analyzed by
WB using anti-V5 and anti-p24 mAbs (Fig. 3b). Of note, despite
massive production due to its ectopic expression (Fig. 3b, cell extract
panel), ADAR1-V5 was not present in non-stimulated Pon A- VLP
samples, but could be detected in all Pon Aþ VLP samples as depicted
in Fig. 3b. These results indicate that Gag alone is sufﬁcient for ADAR1
incorporation into VLPs. Further studies are necessary to investigate in
details the mechanism leading to ADAR1 encapsidation, however
some models can be envisioned.
In particular, a very speculative model forsee that encapsidation
may occur through the interaction of ADAR1 with viral gRNA that is
speciﬁcally bound to p55 Gag for its speciﬁc selection and encapsida-
tion (Lingappa et al., 2014). In support of this hypothesis, it was
previously reported that ADAR1 (Doria et al., 2009) binds and edits
adenosines contained in the poly(A) hairpin and its downstream
sequence in the 50UTR of the 9 kb viral transcript (Doria et al., 2009
and our unpublished results), whereas the p55 Gag binds the stem
and loop 1 (SL1) that initiates dimerization of the gRNA (El-Wahab
et al., 2014). The poly(A) hairpin and the SL1 are very close within the
50 end of the gRNA. Although this assumption is very intriguing, we
don't have data supporting the interaction of ADAR1 with both the
gRNA and the Gag protein within the viral particle. Moreover, we can't
exclude a direct association between p55 Gag and ADAR1 in one of the
high-molecular-mass assembly intermediates leading to the formation
of the HIV-1 immature capsid (Lingappa et al., 2014). In any event, the
more plausible hypothesis is that the interaction of ADAR1 with
diverse cellular RNAs associated to p55 Gag might recruit the enzyme
into viral particles. In support of this hypothesis, we showed that p55
Gag binding to ADAR1 is mostly RNA-dependent and seems to require
the MA sequence. MA domain of p55 Gag was previously reported to
associate with cellular RNAs (Alfadhli and Barklis, 2014; Kutluay et al.,
2014), In any case, the last two hypotheses are in agreement with the
data showing the encapsidation of ADAR1 in VLPs in a cell system not
expressing the whole HIV-1 (i.e. 293 GPR cells).
We previously reported that over-expression of ADAR1 stimulates
the release of HIV-1 virions (Doria et al., 2009). In accordance, it was
shown that knocking-down the expression of ADAR1 in a T cell line
causes an impairment of HIV-1 replication and viral production
(Clerzius et al., 2013). Therefore it can be hypothesized that the
interaction between p55 Gag and ADAR1 is also functional in
supporting one or more steps of virion assembly going from the
immature Gag assembly to the genomic gRNA packaging. This
hypothesis is in agreement with recent data showing that other
cellular proteins, such as ABCE1, DDX6 and Staufen, play a similar role
(Lingappa et al., 1997; Zimmerman et al., 2002; Reed et al., 2012,
Lingappa et al., 2014; Mouland et al., 2000; Chatel-Chaix et al., 2007;
Chatel-Chaix et al., 2008; Milev et al., 2012) but additional
experiments are required to explore this possibility. Moreover, of great
interest will be the elucidation of the role of the ADAR1 enzyme found
in HIV-1 virions.
Conclusions
Taken together, our results results demonstrate that the ADAR1
editing enzyme is incorporated into HIV-1 particles, a phenom-
enon that is likely mediated by the here reported capacity of
ADAR1 to associate with the viral p55 Gag protein
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